Stock Comments / EPS Changes

Amgen (AMGN) estimates, price target were raised at Nomura. Twelve-month price target is now $129. Estimates were also reduced, as the company lacks visibility with its latest guidance, Nomura said. Neutral rating.

Amgen price target, EPS cut at Jefferies AMGN lowered its numbers, Jefferies said. Lower product sales impacted by historical patterns and inventory drawdown. $142 price target and Buy rating.

Centene (CNC) price target, estimates raised at Jefferies CNC lifted its numbers across the board, Jefferies said. Higher revenue trajectory from Duals, Medicaid expansion. $69 price target and Hold rating.

Cree (CREE) estimates, price target were cut at Sterne Agee. Twelve-month price target is now $65. Estimates were also reduced, as the company is realizing lower lighting margins, Sterne Agee said. Buy rating.

Intuitive Surgical (ISRG) price target lowered at Jefferies ISRG cut its number, Jefferies said. Volume deterioration while near term growth is challenging. $465 price target and Buy rating.

Intuitive Surgical numbers were reduced at Sterne Agee. Twelve-month price target is now $360. Estimates were also cut, given weak procedure growth, Sterne Agee said. Underperform rating.

Illinois Tool Works (ITW) price target, EPS raised at Jefferies Shares of ITW reaching $98, according to Jefferies. Upside driven with reacceleration in revenue and margin improvement. Estimates also raised. Buy rating.

Eli Lilly (LLY) price target, EPS bumped up at Jefferies LLY raised its numbers, Jefferies said. Driven by accretive NAH acquisition. $60 price target and Hold rating.

Medidata Solutions (MDSO) price target, EPS cut at Jefferies MDSO lowered its numbers, Jefferies said. Backlog coverage decline. $50 price target and Buy rating.

Skyworks (SWKS) estimates, 12-month price target were raised at Canaccord Genuity. Price target is now $47. Estimates were also increased, given the company's new guidance, Canaccord Genuity said. Buy rating.

United Technologies (UTX) numbers were boosted at Credit Suisse. Twelve-month price target is now $135. Estimates were also increased, given a higher growth outlook, Credit Suisse said. Outperform rating.

Follow TheStreet on Twitter and become a fan on Facebook

This article was written by a staff member of TheStreet.

If you liked this article you might like

Elizabeth Warren Slams Wells Fargo, Equifax: Cramer's Top Takeaways

Centene: Cramer's Top Takeaways

The Pitney Bowes Transformation: Cramer's Top Takeaways

Healthcare Trust of America, Marathon Petroleum: 'Mad Money' Lightning Round

How Long Can This Rally Run?: Cramer's 'Mad Money' Recap (Monday 9/19/17)